

CWM TAF MORGANNWG UNIVERSITY HEALTH BOARD

'UNCONFIRMED' MINUTES OF THE MEETING OF THE EXTRA-ORDINARY PLANNING, PERFORMANCE & FINANCE 'IN COMMITTEE' HELD ON 22 MARCH 2023, AS A VIRTUAL MEETING WHICH WAS HELD VIA MICROSOFT TEAMS

PRESENT

Mel Jehu	-	Independent Member (Chair)
Jayne Sadgrove	-	Health Board Vice- Chair
Carolyn Donoghue	-	Independent Member
Nicola Milligan	-	Independent Member
Ian Wells	-	Independent Member
Patsy Roseblade	-	Independent Member
Dilys Jouvenat	-	Independent Member
Geraint Hopkins	-	Independent Member
Lynda Thomas	-	Independent Member

IN ATTENDANCE

Paul Mears	-	Chief Executive
Linda Prosser	-	Director of Strategy & Transformation
Sally May	-	Director of Finance & Procurement
Gethin Hughes	-	Chief Operating Officer
Hywel Daniel	-	Director for People
Lauren Edwards	-	Director of Therapies & Health Sciences
Richard Hughes	-	Deputy Director of Nursing
Elizabeth Beadle	-	Assistant Director of Transformation
Dom Hurford	-	Medical Director
Stuart Morris	-	Director of Digital
Wendy Penrhyn-Jones	-	Head of Corporate Governance & Board Business
Emma Walters	-	Corporate Governance Manager (Meeting Secretariat)

PART 1. PRELIMINARY MATTERS

1.1.0 WELCOME AND INTRODUCTIONS

The Chair **welcomed** everyone to the meeting.

1.2.0 APOLOGIES FOR ABSENCE

Apologies for absence had been received from Cally Hamblyn, Assistant Director of Governance & Risk.

1.3.0 DECLARATIONS OF INTERESTS

There were no declarations received.

PART 2. MAIN AGENDA

2.1.0 NEW VELINDRE CANCER CENTRE FULL BUSINESS CASE (FBC)

L. Prosser presented the report that provided the Committee with the detail of the Full Business Case that had been reviewed and updated since the Board had approved the Outline Business Case in 2018.

Following a detailed discussion during which members expressed some concerns around the scheme, L Prosser agreed to capture the details in a draft letter to the Chief Executive of NHS Wales. This would accompany the papers around this matter which was due for discussion by the Board at its meeting on 30th March 2023. The concerns were not material to the overall decision that the FBC be endorsed by the Committee for Board approval.

Resolution:

- The Committee
 - **NOTED** that the process to develop the FBC from the previously agreed OBC has followed Treasury Green Book Guidance;
 - **NOTED** the updates made from OBC to FBC and the assurance provided by the Collective Commissioning Group (CCG);
 - **NOTED** the movement in recurrent revenue funding, from the uplifted OBC approved sum, for the Health Board is £301,000. This figure is annual commitment set at 2022-23 price base.
 - **ENDORSED FOR BOARD APPROVAL** the additional investment of £1.449m requested by Velindre NHS Trust from CTMUHB ; This figure is annual commitment set at 2022-23 price base.
 - **ENDORSED FOR BOARD APPROVAL** the Full Business Case, excluding the Commercial Case.
 - **NOTED** that any approval would be subject to the finalisation of the Commercial Case. If there were any changes in the Commercial Case which would have an impact on the Approved status of the other four cases from a commissioner perspective, these cases would be brought back to the Board for consideration.
 - **NOTED** that a letter would be drafted to the Chief Executive of NHS Wales highlighting the concerns raised and this would be added to the meeting papers for consideration at the 'in-committee' meeting of the Health Board on 30th March 2023.

3.0.0 OTHER MATTERS

3.1.0 ANY OTHER URGENT BUSINESS

There was none.

3.1.2 CLOSE OF THE MEETING - DATE AND TIME OF NEXT MEETING:

The next full meeting of the Committee was noted to be scheduled for 26 April 2023 at 2:00 pm.

UNCONFIRMED